Loading
A phase 3 trial of Trastuzumab brengitecan, Trastuzumab emtansine in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy is a phase 3 interventional study registered as NCT06830889 by Sichuan Baili Pharmaceutical Co., Ltd., with 1450 participants planned, started 2025-06-03 and due to reach its primary completion in 2031-10. Interventions recorded: BL-M07D1, T-DM1. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab brengitecan, Trastuzumab emtansine, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab brengitecan, Early HER2-positive breast cancer, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/